Core Viewpoint - Fosun Pharma's subsidiary, YaoYao Pharmaceutical, has granted exclusive global rights to develop, use, manufacture, and commercialize GLP-1R agonists, including YP05002, to Pfizer, indicating recognition of the company's innovative R&D capabilities [1] Group 1 - The licensing agreement includes an upfront payment of $15 million and potential milestone payments of up to $35 million based on clinical and commercialization progress [1] - The collaboration is expected to accelerate the clinical development and commercialization of the licensed products globally, benefiting more patients worldwide [1]